NRX Pharmaceuticals's three largest insider shareholders as of September 29, 2026 are Jonathan C Javitt (Director, 1.29Mn shares), Daniel C. Javitt (TenPercentOwner, 987.29K shares), Daniel C. Javitt (TenPercentOwner, 963.48K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Daniel C. Javitt | TenPercentOwner | 0 | 1,950,769 | 1,950,769 | 56.4% | 01 Dec, 2022 |
| 2 | Jonathan C Javitt | Chairman And Chief Scientist | 84,634 | 1,290,000 | 1,374,634 | 39.7% | 17 Dec, 2024 |
| 3 | Chaim Hurvitz | Director | 107,000 | 0 | 107,000 | 3.1% | 11 Sep, 2023 |
| 4 | Aaron Gorovitz | Director | 0 | 10,500 | 10,500 | 0.3% | 11 Sep, 2023 |
| 5 | Stephen H Willard | Chief Executive Officer | 5,000 | 0 | 5,000 | 0.1% | 18 Dec, 2022 |
| 6 | Voorhees Seth Van | Chief Financial Officer | 4,634 | 0 | 4,634 | 0.1% | 18 Dec, 2022 |
| 7 | Patrick John Flynn | Director | 175 | 4,021 | 4,196 | 0.1% | 28 Nov, 2022 |
| 8 | Alessandra Daigneault | General Counsel Secretary | 3,158 | 0 | 3,158 | 0.1% | 02 Nov, 2021 |
| 9 | Herbert Raymond Mcmaster | Director | 1,830 | 0 | 1,830 | 0.1% | 02 Nov, 2021 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 27 Jan, 2026 | Joseph Michael Casper | Chief Operating Officer | Acquired A | 100,000 | $0.00 | $0 | 100,000 | Direct |
| 07 Feb, 2025 | Michael S Abrams | Chief Financial Officer | Acquired A | 50,000 | $0.00 | $0 | 50,000 | Direct |
| 17 Dec, 2024 | Jonathan C Javitt | Chairman And Chief Scientist | Acquired P | 40,000 | $1.17 | $46.80K | 84,634 | Direct |
| 30 Aug, 2023 | Chaim Hurvitz | Director | Acquired P | 70,000 | $2.88 | $201.25K | 57,000 | Direct |
| 30 Aug, 2023 | Aaron Gorovitz | Director | Acquired P | 35,000 | $3.20 | $111.97K | 10,500 | Indirect |
| 23 Aug, 2023 | Jonathan C Javitt | Chief Scientist | Acquired P | 100,000 | $3.30 | $330.00K | 44,633 | Direct |
| 22 Aug, 2023 | Jonathan C Javitt | Chief Scientist | Acquired P | 200,000 | $3.22 | $644.00K | 34,633 | Direct |
| 16 Dec, 2022 | Voorhees Seth Van | Chief Financial Officer | Acquired P | 30,000 | $11.00 | $330.00K | 4,634 | Direct |
| 16 Dec, 2022 | Stephen H Willard | Chief Executive Officer | Acquired P | 50,000 | $11.70 | $585.00K | 5,000 | Direct |
| 25 Nov, 2022 | Voorhees Seth Van | Chief Financial Officer | Acquired P | 8,716 | $11.20 | $97.62K | 872 | Direct |
| 25 Nov, 2022 | Voorhees Seth Van | Chief Financial Officer | Acquired P | 600 | $11.00 | $6.60K | 932 | Direct |
| 25 Nov, 2022 | Voorhees Seth Van | Chief Financial Officer | Acquired P | 7,021 | $11.10 | $77.93K | 1,634 | Direct |
| 07 Dec, 2022 | Jonathan C Javitt | Director, TenPercentOwner | Disposed S | 400,000 | $10.00 | $4.00Mn | 1,290,000 | Indirect |
| 29 Nov, 2022 | Daniel C. Javitt | TenPercentOwner | Disposed S | 13,730 | $15.04 | $206.51K | 964,323 | Indirect |
| 30 Nov, 2022 | Daniel C. Javitt | TenPercentOwner | Disposed S | 8,441 | $15.05 | $127.00K | 963,479 | Indirect |
| 25 Nov, 2022 | Voorhees Seth Van | Chief Financial Officer | Acquired P | 8,716 | $11.20 | $97.62K | 872 | Indirect |
| 28 Nov, 2022 | Patrick John Flynn | Director | Acquired P | 2,500 | $12.50 | $31.25K | 3,771 | Indirect |
| 28 Nov, 2022 | Patrick John Flynn | Director | Acquired P | 2,500 | $12.50 | $31.25K | 4,021 | Indirect |
| 25 Nov, 2022 | Voorhees Seth Van | Chief Financial Officer | Acquired P | 600 | $11.00 | $6.60K | 932 | Indirect |
| 25 Nov, 2022 | Voorhees Seth Van | Chief Financial Officer | Acquired P | 7,021 | $11.10 | $77.93K | 1,638 | Indirect |